Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis

Hyo Young Lee, Dae Won Jun, Hyun Jung Kim, Hyunwoo Oh, Waqar Khalid Saeed, Hyeong Sik Ahn, Ramsey C. Cheung, Mindie H. Nguyen

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background/Aims: A number of clinical trials reported varying effects of cholesterol lowering agents in nonalcoholic fatty liver disease (NAFLD) patients. We, therefore, assessed the changes in hepatic steatosis and NAFLD activity score (NAS) after treatment with cholesterol lowering agents in NAFLD patients by meta-analysis. Methods: The Cochrane Library, the MEDLINE, and the Embase databases were searched until May 2015, without any language restrictions, for randomized controlled trials (RCTs) and nonrandomized studies (NRSs). Additional references were obtained from review of bibliography of relevant articles. The quality of evidence was assessed using the grading of recommendations assessment, development and evaluation guidelines. Results: Three RCTs (n = 98) and two NRSs (n = 101) met our study inclusion criteria (adult, NAFLD, liver biopsy). Liver biopsy was performed in all five studies, but only the three studies reported NAS. Ezetimibe significantly decreased NAS (standardized mean difference [SMD], –0.30; 95% confidence interval [CI], –0.57 to –0.03) but not hepatic steatosis in RCT (SMD, –0.1; 95% CI, –0.53 to 0.32), while the effect was significant for both NAS and intrahepatic content in NRSs (SMD, –3.0; 95% CI, –6.9 to 0.91). Conclusions: Ezetimibe decreased NAS without improving hepatic steatosis.

Original languageEnglish
Pages (from-to)296-304
Number of pages9
JournalKorean Journal of Internal Medicine
Volume34
Issue number2
DOIs
Publication statusPublished - 2019 Mar 1

Fingerprint

Liver
Randomized Controlled Trials
Confidence Intervals
Cholesterol
Biopsy
Non-alcoholic Fatty Liver Disease
Ezetimibe
Bibliography
MEDLINE
Libraries
Meta-Analysis
Language
Clinical Trials
Databases
Guidelines
Therapeutics

Keywords

  • Ezetimibe
  • Hydroxymethylglu-taryl-CoA reductase inhibitors
  • Meta-analysis
  • Non-alcoholic fatty liver disease

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis. / Lee, Hyo Young; Jun, Dae Won; Kim, Hyun Jung; Oh, Hyunwoo; Saeed, Waqar Khalid; Ahn, Hyeong Sik; Cheung, Ramsey C.; Nguyen, Mindie H.

In: Korean Journal of Internal Medicine, Vol. 34, No. 2, 01.03.2019, p. 296-304.

Research output: Contribution to journalArticle

Lee, Hyo Young ; Jun, Dae Won ; Kim, Hyun Jung ; Oh, Hyunwoo ; Saeed, Waqar Khalid ; Ahn, Hyeong Sik ; Cheung, Ramsey C. ; Nguyen, Mindie H. / Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis. In: Korean Journal of Internal Medicine. 2019 ; Vol. 34, No. 2. pp. 296-304.
@article{0ccc39b78454440c831cf9592ee74c4c,
title = "Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis",
abstract = "Background/Aims: A number of clinical trials reported varying effects of cholesterol lowering agents in nonalcoholic fatty liver disease (NAFLD) patients. We, therefore, assessed the changes in hepatic steatosis and NAFLD activity score (NAS) after treatment with cholesterol lowering agents in NAFLD patients by meta-analysis. Methods: The Cochrane Library, the MEDLINE, and the Embase databases were searched until May 2015, without any language restrictions, for randomized controlled trials (RCTs) and nonrandomized studies (NRSs). Additional references were obtained from review of bibliography of relevant articles. The quality of evidence was assessed using the grading of recommendations assessment, development and evaluation guidelines. Results: Three RCTs (n = 98) and two NRSs (n = 101) met our study inclusion criteria (adult, NAFLD, liver biopsy). Liver biopsy was performed in all five studies, but only the three studies reported NAS. Ezetimibe significantly decreased NAS (standardized mean difference [SMD], –0.30; 95{\%} confidence interval [CI], –0.57 to –0.03) but not hepatic steatosis in RCT (SMD, –0.1; 95{\%} CI, –0.53 to 0.32), while the effect was significant for both NAS and intrahepatic content in NRSs (SMD, –3.0; 95{\%} CI, –6.9 to 0.91). Conclusions: Ezetimibe decreased NAS without improving hepatic steatosis.",
keywords = "Ezetimibe, Hydroxymethylglu-taryl-CoA reductase inhibitors, Meta-analysis, Non-alcoholic fatty liver disease",
author = "Lee, {Hyo Young} and Jun, {Dae Won} and Kim, {Hyun Jung} and Hyunwoo Oh and Saeed, {Waqar Khalid} and Ahn, {Hyeong Sik} and Cheung, {Ramsey C.} and Nguyen, {Mindie H.}",
year = "2019",
month = "3",
day = "1",
doi = "10.3904/kjim.2017.194",
language = "English",
volume = "34",
pages = "296--304",
journal = "Korean Journal of Internal Medicine",
issn = "0494-4712",
publisher = "Korean Association of Internal Medicine",
number = "2",

}

TY - JOUR

T1 - Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis

AU - Lee, Hyo Young

AU - Jun, Dae Won

AU - Kim, Hyun Jung

AU - Oh, Hyunwoo

AU - Saeed, Waqar Khalid

AU - Ahn, Hyeong Sik

AU - Cheung, Ramsey C.

AU - Nguyen, Mindie H.

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Background/Aims: A number of clinical trials reported varying effects of cholesterol lowering agents in nonalcoholic fatty liver disease (NAFLD) patients. We, therefore, assessed the changes in hepatic steatosis and NAFLD activity score (NAS) after treatment with cholesterol lowering agents in NAFLD patients by meta-analysis. Methods: The Cochrane Library, the MEDLINE, and the Embase databases were searched until May 2015, without any language restrictions, for randomized controlled trials (RCTs) and nonrandomized studies (NRSs). Additional references were obtained from review of bibliography of relevant articles. The quality of evidence was assessed using the grading of recommendations assessment, development and evaluation guidelines. Results: Three RCTs (n = 98) and two NRSs (n = 101) met our study inclusion criteria (adult, NAFLD, liver biopsy). Liver biopsy was performed in all five studies, but only the three studies reported NAS. Ezetimibe significantly decreased NAS (standardized mean difference [SMD], –0.30; 95% confidence interval [CI], –0.57 to –0.03) but not hepatic steatosis in RCT (SMD, –0.1; 95% CI, –0.53 to 0.32), while the effect was significant for both NAS and intrahepatic content in NRSs (SMD, –3.0; 95% CI, –6.9 to 0.91). Conclusions: Ezetimibe decreased NAS without improving hepatic steatosis.

AB - Background/Aims: A number of clinical trials reported varying effects of cholesterol lowering agents in nonalcoholic fatty liver disease (NAFLD) patients. We, therefore, assessed the changes in hepatic steatosis and NAFLD activity score (NAS) after treatment with cholesterol lowering agents in NAFLD patients by meta-analysis. Methods: The Cochrane Library, the MEDLINE, and the Embase databases were searched until May 2015, without any language restrictions, for randomized controlled trials (RCTs) and nonrandomized studies (NRSs). Additional references were obtained from review of bibliography of relevant articles. The quality of evidence was assessed using the grading of recommendations assessment, development and evaluation guidelines. Results: Three RCTs (n = 98) and two NRSs (n = 101) met our study inclusion criteria (adult, NAFLD, liver biopsy). Liver biopsy was performed in all five studies, but only the three studies reported NAS. Ezetimibe significantly decreased NAS (standardized mean difference [SMD], –0.30; 95% confidence interval [CI], –0.57 to –0.03) but not hepatic steatosis in RCT (SMD, –0.1; 95% CI, –0.53 to 0.32), while the effect was significant for both NAS and intrahepatic content in NRSs (SMD, –3.0; 95% CI, –6.9 to 0.91). Conclusions: Ezetimibe decreased NAS without improving hepatic steatosis.

KW - Ezetimibe

KW - Hydroxymethylglu-taryl-CoA reductase inhibitors

KW - Meta-analysis

KW - Non-alcoholic fatty liver disease

UR - http://www.scopus.com/inward/record.url?scp=85062613880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062613880&partnerID=8YFLogxK

U2 - 10.3904/kjim.2017.194

DO - 10.3904/kjim.2017.194

M3 - Article

VL - 34

SP - 296

EP - 304

JO - Korean Journal of Internal Medicine

JF - Korean Journal of Internal Medicine

SN - 0494-4712

IS - 2

ER -